Rabbit Polyclonal AKR1A1 Antibody

+ +

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain, cerebellun using S100B mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain (A) and human thymus tissues (B), showing cytoplasmic localization using S100B mouse mAb with DAB staining.    

  
  

The AKR1A1 antibody is a crucial tool for studying the aldo-keto reductase family 1 member A1 (AKR1A1), an enzyme involved in various metabolic pathways. AKR1A1 catalyzes the reduction of carbonyl-containing compounds, including the conversion of L-gulonic acid γ-lactone to vitamin C (ascorbic acid) in some species, and participates in detoxifying reactive aldehydes generated during oxidative stress. It plays roles in cellular homeostasis, glucose metabolism, and antioxidant defense, with implications in diabetes, neurodegenerative disorders, and cancer.

The antibody specifically detects AKR1A1 protein in applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), enabling researchers to analyze its expression levels, tissue distribution, and subcellular localization (primarily cytosolic). It is often validated using knockout cell lines or tissues to confirm specificity, ensuring minimal cross-reactivity with related enzymes like AKR1B1 or AKR1C isoforms.

Commercial AKR1A1 antibodies are typically raised in rabbits or mice using peptide antigens corresponding to conserved regions of the human or murine protein. Their development supports investigations into AKR1A1's physiological functions, regulatory mechanisms (e.g., transcriptional control by Nrf2), and pathological contributions, such as modulating drug resistance or oxidative damage. Reliable AKR1A1 antibodies are essential for advancing research in metabolic diseases, aging, and redox biology.